Bayer is hoping that a new electronic autoinjector will slow the fall of lucrative multiple sclerosis drug Betaseron off of the dreaded patent expiry sales cliff.
"Cover all the bases" is the theme of FierceDrugDelivery's annual list of the top drug delivery partnerships. Finding 10 significant alliances that represent the full range of drug delivery advances was a challenge, and there are certainly other deals out there that are both novel and of high importance.
Still, the tie-ups highlighted here represent the arena's diversity on multiple levels. Half of the deals involve use of drug delivery devices like "smart" inhalers and drug-coated angioplasty balloons, while others focus on the molecular aspects, like transportation across biological barriers and the development of formulations that are efficacious and/or differentiate the medication.
We considered deals that commenced in 2014 and so far in 2015.
Cambridge, MA's Ra Pharma received $58.5 million from a mix of strategic and VC investors to take on Alexion's intravenously infused orphan drug Soliris with a cheaper, subcutaneously delivered alternative. Its preclinical peptide-inhibiting candidate aims to shake up the paroxysmal nocturnal hemoglobinuria market using an alternative form of drug delivery. Read more >>
POPULAR COMMENT THREADS
Intarcia, the maker of a subdermal pump for once-a-year diabetes drug delivery, added optimized peptides to its arsenal via the acquisition of the Research Triangle's Phoundry Pharmaceuticals. It's the first-ever acquisition for Intarcia, which seeks additional compounds to deliver via its investigational drug delivery device, dubbed ITCA 650.
Microneedle patches have long been seen as a potential alternative to needles to treat, for instance, diabetes, eye conditions or cancer. Producing the tiny needles, though, is difficult and costly. But a team of scientists from the University of Akron and the University of Texas has now developed a technique for manufacturing the transdermal arrays using a process called microstereolithography.
Pennsylvania startup Genisphere locked down a $4 million investment to expand its DNA-based drug delivery platform, looking to finish the preclinical process and license the technology to pharma partners.
GlaxoSmithKline now has rights to develop inhaled therapeutics using Liquidia's PRINT particle engineering technology. The development builds on a drug delivery alliance between the two companies that commenced in 2012.
Hospi announced CE-mark approval for its flagship Macy Catheter, the only device on the market that's designed specifically for rectal delivery of fluids and medications.
Precision NanoSystems completed a $13.4 million Series A round to back its NanoAssemblr platform for the targeted delivery of nanoparticles and diagnostic agents.
From Our Sister Sites
India's Aurobindo Pharma recently laid out plans to build three new plants in India in the next three years. The drugmaker also intends to bulk up capacity at a bulk drug plant and got the OK from India's environmental regulator for the fourfold expansion.
China FDA has issued four guidance documents to improve its oversight of the country's device industry.